Ivabradine Ranbaxy (Ivabradine Hydrochloride)

Ivabradine hydrochloride, the active ingredient in Ivabradine Ranbaxy, is a If channel inhibitor presented as an oral tablet for oral use. It is used to lower heart rate in patients with chronic stable angina and heart failure with reduced ejection fraction. GNH USA supplies Ivabradine Ranbaxy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine Ranbaxy acts on the cardiac If current to manage conditions where heart‑rate reduction is beneficial.

Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. Heart failure with reduced ejection fraction: improves symptoms and exercise capacity by decreasing myocardial oxygen demand. Symptomatic tachycardia in angina patients: provides rate control when beta‑blockers are contraindicated.

Ivabradine may cause a range of adverse reactions.

Common Side Effects: - Bradycardia: resting heart rate falls below 50 bpm. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other supraventricular arrhythmias. - Symptomatic hypotension. - High‑grade atrioventricular block. - Acute coronary syndrome in susceptible patients.

Before initiating therapy, clinicians should assess cardiac status and monitor heart rate.

Monitor heart rate: ensure resting HR > 50 bpm before starting. Avoid in severe hepatic impairment: dose adjustment may be required. Caution with concomitant beta‑blockers: increased risk of excessive bradycardia. Assess for visual disorders: discontinue if persistent phosphenes occur. Pregnancy and lactation: use only if potential benefit justifies risk. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Ivabradine's pharmacokinetics can be altered by several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase exposure. - Co‑administration with other heart‑rate‑lowering agents (beta‑blockers, digoxin, verapamil): risk of severe bradycardia. - Concomitant use with diltiazem: can elevate plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive agents: monitor blood pressure for additive effects. - Alcohol: may potentiate bradycardic response.